Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Positioning at the Center of Critical Materials, Innovation

Posted on June 6, 2025 by MissionIR

Platinum Group Metals (NYSE American: PLG) (TSX: PTM) is strategically positioning itself for growth amid strong palladium market dynamics, driven by constrained supply and continued industrial demand. With palladium essential in automotive, electronics, and emerging clean energy applications, the company is advancing the Waterberg Project in South Africa—one of the largest undeveloped primary palladium and platinum projects globally. In partnership with Anglo American Platinum Limited, PLG is also investing in future-focused innovation through Lion Battery Technologies, which explores the use of platinum and palladium in next-generation lithium battery technologies. Among the few companies combining traditional mining development with tech-driven diversification, Platinum Group Metals offers a compelling opportunity in the evolving critical materials market.

To view the full article, visit https://ibn.fm/Ss2JZ

About Platinum Group Metals Ltd.

Platinum Group Metals is the operator of the Waterberg Project, a bulk underground palladium and platinum deposit located in South Africa. The Waterberg Project was discovered by Platinum Group and is being jointly developed with Implats, Mnombo and HJM. For more information about the company, visit www.PlatinumGroupMetals.net.

NOTE TO INVESTORS: The latest news and updates relating to PLG are available in the company’s newsroom at https://ibn.fm/PLG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Platinum Group Metals Ltd. PLG | Leave a comment

MissionIRNewsBreaks – Why Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’

Posted on June 6, 2025 by MissionIR

Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. INBS was featured in a recent article that reads, “By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings… The company’s vision is to redefine drug screening by removing the pain points of traditional testing methods, including biohazardous waste, privacy concerns, and long result turnaround times. With results in under 10 minutes and no need for gender-specific collectors or laboratory facilities, the system empowers companies and organizations to screen more efficiently. INBS continues to drive adoption in international markets, with customers spanning construction, logistics, healthcare, government, and drug treatment sectors.”

To view the full article, visit https://ibn.fm/u85ZW

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit the company’s website at www.ibs.inc.

NOTE TO INVESTORS: The latest news and updates relating to INBS are available in the company’s newsroom at http://ibn.fm/INBS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Intelligent Bio Solutions Inc. INBS | Leave a comment

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25 as U.S. Expansion Advances

Posted on June 6, 2025 by MissionIR
  • The company’s non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates.
  • Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings.
  • INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity.
  • The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety.
  • INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery.

Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies (https://ibn.fm/1JSTS).

The event, held May 28–31 in Florida, attracted over 7,000 professionals from the fields of addiction treatment, mental health, and criminal justice. The conference has become a national gathering point for those working on evidence-based approaches to substance use and behavioral health issues.

At the conference, INBS presented its system alongside its U.S. distribution partner SMARTOX. SMARTOX, founded in 2012, provides drug and alcohol testing services across a wide range of institutional settings in the United States. The firm offers a full-service model, including distribution, customer support, and program design.

INBS’s drug screening system, designed for forensic use in the United States, detects recent drug use by analyzing fingerprint sweat. It screens for cannabis, cocaine, methamphetamine, and opiates, producing results in under ten minutes.

INBS President and CEO Harry Simeonidis and Vice President of Global Sales Doug Heath were present at the event, joining SMARTOX’s Vice President of Sales and Marketing, Duffy Nabors, in demonstrating the system’s potential applications.

The system’s portability and ease of use are well-suited to environments where rapid screening and privacy are important, such as treatment courts, probation programs, and correctional settings. The fingerprint sweat-based system offers an alternative to traditional urine or saliva tests, with less need for invasive procedures or secure facilities.

Heath emphasized the importance of delivering “effective screening methods for justice-involved individuals,” particularly in programs focused on recovery and rehabilitation rather than incarceration. “The RISE conference represents a national effort to transform justice responses to substance use and mental health,” said Heath. “We’re proud to support SMARTOX in showcasing our solution and to contribute to the conversation around dignity, access, and effective screening methods for justice-involved individuals.”

The company’s attendance at RISE25 reflects its broader strategy to position the technology in the U.S. justice and public health sectors. Currently, the system is approved only for forensic use in the U.S., but INBS is seeking broader FDA clearance.

Outside the U.S., the company’s drug testing system is already deployed in sectors such as construction, manufacturing, transport, and drug treatment. In total, INBS reports more than 450 active accounts across 24 countries, reflecting growing global interest in rapid, on-site testing tools.

For INBS, the U.S. forensic market offers a testbed for its system, while regulatory progress may open up opportunities in other high-demand areas such as workplace safety and healthcare. The company’s participation in RISE25 provided a direct channel to policymakers, researchers, and court officials interested in more efficient screening methods.

For more information, visit the company’s website at https://ibs.inc.

NOTE TO INVESTORS: The latest news and updates relating to INBS are available in the company’s newsroom at http://ibn.fm/INBS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Intelligent Bio Solutions Inc. INBS | Leave a comment

Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL

Posted on June 6, 2025 by MissionIR
  • Soligenix’s HyBryte(TM) is a photodynamic therapy using synthetically manufactured hypericin, one of the most photoactive compounds available.
  • The therapeutic potential of HyBryte(TM) has been demonstrated through multiple clinical trials, including a Phase 3 trial in early-stage CTCL patients.
  • HyBryte(TM) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency.

Cutaneous T-cell lymphoma (“CTCL”) is a rare and debilitating form of non-Hodgkin’s lymphoma that primarily affects the skin, posing both physical and emotional challenges for those diagnosed. With limited treatment options available and no definitive cure, the need for innovative, safe and effective therapies is urgent. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is focused on developing and commercializing products to treat rare diseases. At the forefront of Soligenix’s pipeline is HyBryte(TM), a novel therapy aimed at treating early-stage CTCL.

CTCL affects the skin by causing malignant T-cells to accumulate in the upper layers, often resulting in patches, plaques and tumors that can be intensely itchy, painful, and disfiguring. The disease can significantly impair quality of life and, in more advanced stages, may involve other parts of the body such as the lymph nodes, blood and internal organs.

According to the Cutaneous Lymphoma Foundation, approximately 3,000 new cases of CTCL are diagnosed in the United States each year, with an estimated 30,000 to 40,000 individuals living with the disease nationwide (https://ibn.fm/Rh6HC). While CTCL tends to progress slowly, it is chronic and currently incurable, requiring ongoing treatment to manage symptoms and improve patients’ quality of life.

This chronic nature makes the search for better treatment solutions even more critical, especially as existing therapies often involve systemic immunosuppressants, phototherapy or chemotherapy, which can carry serious side effects and limit long-term effectiveness. The need for treatments that are not only effective but also safe and tolerable over long durations is pressing.

Soligenix’s HyBryte(TM) (synthetic hypericin) is a photodynamic therapy using synthetically manufactured hypericin, which is one of the most photoactive compounds available (https://ibn.fm/6L6oR). Used in ointment or gel form, synthetic hypericin is combined with visible fluorescent or LED light. Because it is easily activated with relatively low-energy light, HyBryte(TM) is ideal for photodynamic therapy because it can be activated with safe visible light instead of damaging UVA or UVB light, which are associated with increased cancer risks.

This mechanism is particularly significant in treating CTCL, a condition that often requires repeated and prolonged skin treatments. HyBryte(TM) offers a noninvasive alternative that may reduce the cumulative toxicity and side effects often seen with current options.

The therapeutic potential of HyBryte(TM) has been demonstrated in multiple clinical trials, including a Phase 3 trial in early-stage CTCL patients. The company recently released interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) treatment for up to 54 weeks in patients with early-stage CTCL (https://ibn.fm/N3np8). Following 18 weeks of treatment, 75% of patients achieved “treatment success,” reinforcing HyBryte(TM) as a potentially safe and fast-acting therapy for this chronic and underserved cancer.

In January 2025, Soligenix announced expanded access treatment results that also showed positive outcomes, reinforcing the drug’s safety and efficacy profile in real-world applications (https://ibn.fm/ntbfY). Patients who continued treatment beyond the original trial timeline maintained or improved their clinical responses, a particularly encouraging outcome in the management of a disease known for its relapsing and remitting course.

HyBryte(TM) has also been granted Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”), which provides regulatory incentives including market exclusivity, tax credits for clinical testing, and exemption from user fees. This designation not only underscores the drug’s potential to address an unmet medical need but also enhances its commercial viability, if approved. Furthermore, Soligenix has expressed intentions to pursue marketing approval worldwide, including the European Union, where HyBryte(TM) has also received Orphan Drug Designation from the European Medicines Agency (“EMA”), which could pave the way for broader access to the treatment and significant benefits for patients globally.

In addition, Soligenix is engaging with the broader medical and scientific communities to ensure HyBryte’s(TM) integration into treatment protocols, should regulatory approval be granted. As the company continues to build on its clinical successes, its commitment to innovation in rare disease treatment remains clear. The development of HyBryte(TM) for CTCL reflects Soligenix’s broader mission: to deliver novel treatment solutions for underserved patient populations. With the increasing prevalence of CTCL and the limited scope of current treatment options, HyBryte(TM) could represent a much-needed breakthrough in how the disease is managed, offering new hope to thousands of individuals living with this complex and chronic lymphoma.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Soligenix Inc. SNGX | Leave a comment

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

Posted on June 5, 2025 by MissionIR
  • The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics.
  • HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25.
  • Kadima specializes in interventional psychiatry, and Kadima’s founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer.
  • NRx’s broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, known for treating suicidal bipolar depression and acute suicidal depression, has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute. The Kadima acquisition agreement (not yet closed) is part of HOPE’s strategy to establish a scalable mental health treatment network of interventional psychiatry clinics. (https://ibn.fm/DjOMz).

Kadima, located in La Jolla, California, will become the clinical and operational template for the proposed network. Known for its work in interventional psychiatry, the clinic’s integration with HOPE Therapeutics is expected to drive immediate financial gains, including EBITDA growth.

HOPE Therapeutics is targeting the acquisition of up to 30 clinics by the end of 2025, with a $100 million pro forma run rate by YE 25. The company is positioning these clinics to address critical gaps in care for patients experiencing suicidal depression, post-traumatic stress disorder, and other complex mental health conditions.

Dr. David Feifel, founder of Kadima and a recognized figure in interventional psychiatry, will take on the role of Chief Medical Innovation Officer at HOPE Therapeutics. His appointment is viewed as a key asset for the company’s clinical strategy. “Dr. David Feifel is a true pioneer in interventional psychiatry and we are honored to have him join our leadership team,” said HOPE Co-CEOs Dr. Jonathan Javitt and Matthew Duffy. “With his guidance, we are accelerating the buildout of a world-class clinic network that integrates cutting-edge science with community-based care.”

The acquisition of Kadima is part of a broader expansion by HOPE Therapeutics into the outpatient psychiatric treatment space. Additional agreements are already in place to acquire Dura Medical and a letter of intent has been signed with Neurospa TMS. This expansion reflects growing demand for more accessible, evidence-based interventions in psychiatric care, including ketamine-based treatments and neuromodulation techniques.

Kadima’s offerings include therapies that go beyond conventional medication management, reflecting a rising interest among investors and healthcare providers in new psychiatric modalities.

NRx Pharmaceuticals is concurrently advancing a drug development pipeline focused on central nervous system (“CNS”) disorders. Its lead asset, NRX-101, has received Breakthrough Therapy Designation from the FDA for treatment-resistant bipolar depression with acute suicidality. Another program, NRX-100, a preservative-free IV formulation of ketamine, has Fast Track status and is aimed at acute suicidality treatment.

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Italian Clearance for Option to Acquire Biotech Firm Pincell

Posted on June 5, 2025 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has received regulatory clearance under Italy’s Golden Power regulation to proceed with its option to acquire 100% of Pincell S.r.l., an Italian biotech company. The approval, issued by Italy’s Coordination Group and Ministry of Health, supports Scinai’s strategic move to expand its inflammation and immunology pipeline. Pincell’s lead asset, PC111—a monoclonal antibody targeting the Fas/FasL pathway—holds Orphan Drug Designation in Pemphigus and is being developed for severe skin disorders. The acquisition remains subject to final conditions, including a €12 million grant decision expected later this summer.

To view the full press release, visit https://ibn.fm/qoRQ1

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit

Posted on June 5, 2025 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled “The Future and Promise of TPI 287,” will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma patients, including 3 complete and 9 partial responses in a Phase 1 trial. TPI 287, which has FDA Orphan Drug Designation for gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, may offer a breakthrough in treating CNS tumors by effectively crossing the blood-brain barrier.

To view the full press release, visit https://ibn.fm/3W6HS

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Posted on June 5, 2025 by MissionIR
  • Buprenorphine is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder and chronic and severe pain
  • Nutriband is developing a novel transdermal delivery system for buprenorphine, projected to reach peak annual sales of $70M – $130M
  • The company’s AVERSA pipeline currently includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine

As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected against misuse, using its proprietary Aversa technology to set a new standard for transdermal pain and addiction treatments.

Buprenorphine, the next candidate for Aversa, is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder (“OUD”) (https://ibn.fm/eQizg). Like NTRB’s Fentanyl patch, it offers an effective and safer alternative to full opioid agonists and has become a cornerstone in medication-assisted treatment (“MAT”) for OUD.

Clinical research supports buprenorphine’s advantages over other opioid treatments. A 2018 study published by the National Institute of Health found that patients with OUD treated with buprenorphine following a nonfatal opioid overdose are associated with significant reductions in opioid related mortality (https://ibn.fm/PYwdo).

NTRB is building on this momentum with their novel transdermal delivery system for buprenorphine, using its patented Aversa abuse-deterrent technology. Rather than relying on traditional oral films or sublingual tablets, Nutriband’s model involves embedding aversive agents into the patch itself, which deters misuse by producing unpleasant effects if the product is tampered with or consumed orally or intravenously. This innovation is especially important given the high rates of misuse associated with even prescribed opioid therapies.

The company’s Aversa pipeline currently includes two main opioid candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine. AVERSA(TM) Fentanyl, Nutriband’s most advanced product, integrates the deterrent system with an FDA-approved fentanyl patch developed by Kindeva Drug Delivery. According to Nutriband, this would be the world’s first abuse-deterrent fentanyl patch, potentially reducing the risk of diversion, misuse and accidental exposure in a category known for both its efficacy and danger.

AVERSA(TM) Buprenorphine, meanwhile, is being positioned as the next step in the company’s growth. In a market update and based off a Health Advances independent report, Nutriband projected potential peak annual sales of $70 million to $130 million for AVERSA(TM) Buprenorphine in the United States alone upon regulatory approval (https://ibn.fm/foAon). The company is also evaluating international commercialization opportunities, supported by its expanding global patent portfolio.

Nutriband’s broader mission is to develop technologies that reduce the potential for abuse and misuse in pain and addiction treatment. The Aversa platform is designed to be applied to a range of transdermal therapies beyond fentanyl and buprenorphine, potentially addressing multiple categories of prescription misuse. The company believes that its approach could help bridge the gap between effective treatment and public health responsibility in the ongoing fight against opioid-related harm.

As regulators, physicians and patients alike seek new tools to battle the opioid epidemic, Nutriband’s efforts could prove pivotal. If successfully commercialized, Aversa-based products may offer a much-needed blend of efficacy, safety and innovation in a space that has long been fraught with challenges. 

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Nutriband Inc. NTRB | Leave a comment

MissionIRNewsBreaks – SolarBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) to Allocate Solar Project Revenue to Bitcoin Treasury Strategy

Posted on June 5, 2025 by MissionIR

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has taken its first step toward implementing a Bitcoin treasury strategy by committing net revenue from its 3.79 MW Geddes Solar Power Project to Bitcoin purchases. This initiative places SolarBank among the early renewable energy companies integrating digital assets into corporate finance. The Geddes Project, built on a repurposed landfill, is expected to begin operations by the end of June 2025. CEO Dr. Richard Lu described the move as a strategic blend of stable energy cash flow and Bitcoin’s appreciation potential, with future expansions of the strategy under evaluation across the company’s clean energy portfolio.

To view the full press release, visit https://ibn.fm/jVVDg

About SolarBank Corporation

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA. The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built. For more information, visit the company’s website at SolarBankCorp.com. This report contains forward looking information. Please refer to https://ibn.fm/q3cv3 https://ibn.fm/oEJ7e for additional details.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in SolarBank Corp. SUUN | Leave a comment

Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) Is ‘One to Watch’

Posted on June 5, 2025 by MissionIR
  • Fiscal 2025 marked record revenues of nearly $299 million, with silver production of 6.9 million ounces and 11% year-over-year growth in silver equivalent output.
  • The company maintains industry-leading margins with an all-in sustaining cost of $12.12 per ounce of silver over the last 12 months, reinforcing its position as a low-cost producer.
  • The company maintains a strong balance sheet with over $369 million in cash and a strategic equity portfolio, ensuring financial flexibility for future growth.
  • The company launched construction of its fully funded El Domo copper-gold mine in 2025, with production expected by the end of 2026.
  • Silvercorp has published an updated mineral resource estimate for the Condor Project and expects to issue a revised PEA by year-end 2025.
  • Silvercorp is committed to strong environmental and social governance practices, holding an MSCI ESG rating of “A” and prioritizing local employment and procurement.

Silvercorp Metals (NYSE American: SVM) (TSX: SVM) is a Canadian mining company producing silver, gold, lead, and zinc, with a long history of profitability and growth. The company focuses on creating shareholder value by generating free cash flow from long-life mines, expanding through organic growth opportunities in China and Ecuador, and pursuing strategic mergers and acquisitions. Silvercorp has built a reputation as a low-cost producer with a commitment to responsible mining practices.

With over 18 years of operating experience, Silvercorp has developed a diversified portfolio of mining assets and investments in China, Ecuador, and Bolivia. The company leverages its expertise in exploration and operational efficiency to enhance the value of its projects while maintaining a strong balance sheet. Silvercorp’s disciplined approach to mine expansion and resource development ensures long-term sustainable growth.

The company’s mission is to build and operate profitable mines that generate sustainable economic, social, and environmental benefits for stakeholders. Silvercorp is committed to responsible mining, with a focus on environmental stewardship and community engagement.

The company is headquartered in Vancouver, Canada.

Portfolio

Silvercorp operates a diverse portfolio of producing mines, construction-stage projects, and exploration assets across multiple jurisdictions. The company focuses on optimizing production from existing operations while strategically advancing new projects to drive future growth.

  • Ying Mining District (China) – The company’s flagship operation consists of several underground mines producing silver, gold, lead and zinc in concentrates. In fiscal 2025, Ying produced 6.9 million ounces of silver and 7,495 ounces of gold, along with lead and zinc by-products. Fiscal 2026 guidance calls for continued production growth as ongoing mine optimization efforts continue to bear fruit.
  • GC Mine (China) – A silver-lead-zinc mine with a history of consistent production and ongoing resource expansion through drilling. While production dipped slightly in fiscal 2025, output is expected to increase in fiscal 2026.
  • El Domo (Ecuador) – A fully-permitted, copper-gold project under construction. In April 2025, Silvercorp announced a detailed and fully funded $240.5 million construction plan. Major contracts have been awarded and construction activities are underway, with commissioning expected by December 2026.
  • Condor Project (Ecuador) – A gold exploration asset with significant resources. In May 2025, Silvercorp published an updated mineral resource estimate focusing on high-grade underground zones. A revised PEA is expected by the end of 2025, alongside continued permitting and community engagement efforts.
  • Kuanping Project (China) – A permitted gold-lead-zinc satellite project north of Ying. Mine construction is underway and Kuanping will be an underground mine with ore to be milled at the Ying complex.
  • BYP Mine (China) – A gold-lead-zinc project that operated previously and is now undergoing permitting as a gold mine.
  • Bolivian Assets – Silvercorp holds a 28% stake in New Pacific Metals (TSX: NUAG, NYSE American: NEWP), providing indirect exposure to two world class silver projects: Silver Sand and Carangas.

Through its diversified portfolio, Silvercorp delivers exposure to operations generating growing cash-flow, as well as high-potential growth projects that will create long-term value for shareholders.

Market Opportunity

The global demand for silver, gold, and base metals remains strong, driven by industrial applications, investment demand, and renewable energy initiatives. Silvercorp is well positioned to capitalize on rising silver demand, particularly in China, where 80% of the world’s solar panels are manufactured—an industry heavily reliant on silver.

Ecuador’s mining sector is experiencing rapid growth, with government support for foreign investment and infrastructure improvements. Mining exports in the country surged from $275 million in 2018 to $3.3 billion in 2023, highlighting the sector’s increasing economic importance. Silvercorp’s El Domo and Condor projects are poised to become key contributors to Ecuador’s mining expansion.

Industry forecasts indicate continued growth in silver and base metal prices, benefiting producers with strong operational performance and cost controls. Silvercorp’s diversified asset base and low-cost production profile provide resilience against market fluctuations, positioning the company for long-term value creation.

Leadership Team

Rui Feng, Ph.D., Chairman and CEO, founded Silvercorp and has over 30 years of experience in mineral exploration and mining. He has been instrumental in leading the company’s strategic vision, transforming it into a profitable, low-cost silver producer with a diversified asset base. Under his leadership, Silvercorp has expanded its global footprint, acquiring and developing high-value mining projects across China, Ecuador, and Bolivia. Dr. Feng’s expertise in geology and resource development has contributed to major mineral discoveries, and his disciplined approach to capital allocation has positioned the company for long-term growth.

Derek Liu, MBA, CGA, CPA, Chief Financial Officer, brings over two decades of financial leadership experience in the mining sector, overseeing capital allocation, financial strategy, and risk management. He has played a crucial role in maintaining Silvercorp’s strong balance sheet and financial discipline, ensuring the company remains well-capitalized for organic growth and strategic acquisitions. His expertise in financial planning, compliance, and investor relations has supported Silvercorp’s continued profitability and operational efficiency in a competitive global mining landscape.

Lon Shaver, CFA, President, has extensive experience in corporate finance, equity research, and capital markets, providing strategic guidance on business development and investor relations. Before joining Silvercorp, he held senior roles in investment banking and asset management, where he advised mining companies on financing, mergers, and acquisitions. His deep understanding of capital markets and industry dynamics helps drive Silvercorp’s corporate growth initiatives, enhance shareholder value, and strengthen relationships with institutional investors and stakeholders.

For more information, visit the company’s website at https://silvercorpmetals.com.

NOTE TO INVESTORS: The latest news and updates relating to SVM are available in the company’s newsroom at https://ibn.fm/SVM

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Silvercorp Metals Inc. SVM | Leave a comment